J&J highlights Tremfya’s efficacy against psoriatic arthritis in Phase 3 trial win
Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...
Barchart on MSN21h
Earnings Preview: What to Expect From Johnson & Johnson's Report
Headquartered in New Brunswick, New Jersey, Johnson & Johnson (JNJ) researches and develops, manufactures, and sells various ...
J&J’s experimental antiviral drug shows promise against COVID-19 and emerging coronaviruses
This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 treatments.
Zacks Investment Research on MSN19h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the ...